Referencing for people who value simplicity, privacy, and speed.Get Citationsy
← Back to Search
Genetic Variants In The Vitamin D Receptor Are Associated With Advanced Prostate Cancer At Diagnosis: Findings From The Prostate Testing For Cancer And Treatment Study And A Systematic Review
L. Chen, G. Davey Smith, D. Evans, A. Cox, D. Lawlor, J. Donovan, W. Yuan, I. Day, R. Martin, A. Lane, S. Rodríguez, Michael T. Davis, L. Zuccolo, S. Collin, F. Hamdy, D. Neal, S. Lewis
Published 2009 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Low levels of plasma vitamin D have been implicated as a possible risk factor for both prostate cancer incidence and advanced disease, and recent phase II trials suggest that vitamin D supplementation might delay progression of prostate cancer. Common polymorphisms in the vitamin D receptor (VDR) are associated with VDR activity and are therefore potentially useful proxies for assessing whether vitamin D is causally related to advanced prostate cancer. We genotyped five well-known VDR polymorphisms in 1,604 men with prostate cancer from the Prostate Testing for Cancer and Treatment study. Our aim was to examine the association between VDR polymorphisms and cancer stage (localized versus advanced) as well as cancer grade (Gleason score <7 versus ≥7). Moreover, we also carried out a systematic review and meta-analysis of 13 similar studies. As a result of our meta-analysis, we revealed three polymorphisms, BsmI, ApaI, and TaqI, associated with high Gleason score with an overall summary odds ratios (95% confidence intervals) of 1.12 (1.00-1.25; bb versus BB + Bb), 1.25 (1.02-1.53; aa versus AA + Aa), and 0.82 (0.69-0.98; Tt + tt versus TT), respectively. The haplotype analysis revealed that the BsmI (B)-ApaI (A)-TaqI (t) participants compared with BsmI (b)-ApaI (a)-TaqI (T) individuals were less likely to have high Gleason scores (odds ratio, 0.84; 95% confidence interval, 0.71-1.00; Punadjusted = 0.050; Padjusted = 0.014). Our finding provides some support for the hypothesis that low levels of vitamin D may increase the risk of prostate cancer progression. (Cancer Epidemiol Biomarkers Prev 2009;18(11):2874–81)
This paper references
'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?
G. Smith (2003)
Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.
A. Chokkalingam (2001)
Vitamin D receptor gene polymorphism in Japanese patients with prostate cancer.
Y. Furuya (1999)
Vitamin D and prostate cancer: a prediagnostic study with stored sera.
E. Corder (1993)
Clustered Environments and Randomized Genes: A Fundamental Distinction between Conventional and Genetic Epidemiology
G. Smith (2007)
The role of Vitamin D3 metabolism in prostate cancer
Y. Lou (2004)
Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population.
S. Huang (2004)
[Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer].
J. Liu (2004)
Recent Progress in the Treatment of Advanced Prostate Cancer With Intermittent Dose-Intense Calcitriol (DN-101).
M. Brawer (2007)
1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo.
G. Schwartz (1995)
Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)
A. Nomura (2004)
Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population
K. Suzuki (2003)
Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
M. Braun (2004)
Vitamin D Receptor Genotypes/Haplotypes and Prostate Cancer Risk
M. Çiçek (2006)
Bahnson RR. 1,25-Dihydroxy-16-ene-23-yne-vitamin D 3 and prostate cancer cell proliferation in vivo
G G Schwartz (1995)
Haploview: analysis and visualization of LD and haplotype maps
J. Barrett (2005)
Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25‐hydroxyvitamin D and 1,25‐dihydroxyvitamin D, and prostate cancer risk
B. Mikhak (2007)
Serum vitamin D metabolite levels and the subsequent development of prostate cancer
AM Nomura (1998)
Cancer Epidemiol Biomarkers Prev
Combination of prostatespecific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer
AW Partin (1997)
Prediction of bone density from vitamin D receptor alleles
N. Morrison (1994)
Vitamin D receptor gene polymorphisms and prostate cancer risk
M. K. Cheteri (2004)
Vitamin D receptor gene polymorphisms and disease free survival after radical prostatectomy
H. Williams (2004)
Vitamin D receptor as an intestinal bile acid
M Makishima (2002)
The Relation of Solar Radiation to Cancer Mortality in North America
F. L. Apperly (1941)
A Prospective Study of Plasma Vitamin D Metabolites, Vitamin D Receptor Polymorphisms, and Prostate Cancer
H. Li (2007)
Prostate cancer epidemiology.
A. Hsing (2006)
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
T. Beer (2007)
Population Substructure and Control Selection in Genome-Wide Association Studies
K. Yu (2008)
Prostate Testing for Cancer and Treatment (ProtecT) feasibility study.
J. Donovan (2003)
Bias in meta-analysis detected by a simple, graphical test
M. Egger (1997)
Significance of Vitamin D Receptor Gene Polymorphism for Risk and Disease Severity of Prostate Cancer and Benign Prostatic Hyperplasia in Japanese
T. Hamasaki (2002)
Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case‐control study in the Nordic countries
P. Tuohimaa (2004)
Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer
E. Jacobs (2004)
The Polymorphism in the Caudal‐Related Homeodomain Protein Cdx‐2 Binding Element in the Human Vitamin D Receptor Gene
H. Arai (2001)
Operating characteristics of a rank correlation test for publication bias.
C. Begg (1994)
TNM residual tumor classification revisited
C. Wittekind (2002)
Comprehensive Association Analysis of the Vitamin D Pathway Genes, VDR, CYP27B1, and CYP24A1, in Prostate Cancer
C. Holick (2007)
Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians.
J. Ma (1998)
Plasma 1,25-Dihydroxy- and 25-Hydroxyvitamin D and Subsequent Risk of Prostate Cancer
E. Platz (2004)
Circulating vitamin D metabolites in relation to subsequent development of prostate cancer.
P. Gann (1996)
Haplo.stats: statistical analysis of haplotypes with traits and covariates when linkage phase is ambiguous: R package version
JP Sinnwell (2005)
Prostate cancer and prediagnostic levels of serum vitamin D metabolites
MM Braun (1995)
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
A. Partin (1997)
Androgen receptor and vitamin D receptor in human ovarian cancer: Growth stimulation and inhibition by ligands
M. Ahonen (2000)
Vitamin D Receptor As an Intestinal Bile Acid Sensor
M. Makishima (2002)
The polymorphic N terminus in human vitamin D receptor isoforms influences transcriptional activity by modulating interaction with transcription factor IIB.
P. Jurutka (2000)
Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes
C. Luscombe (2001)
stats: statistical analysis of haplotypes with traits and covariates when linkage phase is ambiguous: R package version 1.2.2
J P Sinnwell (2005)
Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy
S. Huang (2006)
Vitamin D receptor polymorphisms and prostate cancer
D. G. Blazer (2000)
Vitamin D receptor gene polymorphism and prostate cancer risk
A. Gsur (2002)
Vitamin D receptor ( VDR ) gene polymorphisms and haplotypes , interactions with plasma 25 - hydroxyvitamin D and 1 , 25 - dihydroxyvitamin D , and
Vitamin D metabolism in peripheral blood mononuclear cells is influenced by chewing "betel nut" (Areca catechu) and vitamin D status.
W. Ogunkolade (2006)
Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recurrence after radical prostatectomy
T. Steuber (2006)
Potentiation of the growth-inhibitory effects of vitamin D in prostate cancer by genistein.
A. Krishnan (2007)
Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: inhibition of the prostaglandin pathway.
Jacqueline Moreno (2006)
This paper is referenced by
Molecular Testing in Prostate Cancer
M. Gabril (2014)
Association of Vitamin D Receptor Gene Variation With Osteoporosis Risk in Belarusian and Lithuanian Postmenopausal Women
P. Marozik (2018)
Vitamin D and urological cancers
W. Krajewski (2016)
Vitamin D and aging: beyond calcium and bone metabolism.
F. Pérez-López (2011)
C-Reactive Protein Levels and Vitamin D Receptor Polymorphisms as Markers in Predicting Cachectic Syndrome in Cancer Patients
T. Punzi (2012)
The role of vitamin D in reducing cancer risk and progression
D. Feldman (2014)
Hormone response element binding proteins: Novel regulators of vitamin D and estrogen signaling
Thomas S. Lisse (2011)
Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case–control study
R. Gilbert (2014)
Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer
Jiunn-Bey Pao (2011)
Vitamin D Receptor Cdx-2 Polymorphism and Premenopausal Breast Cancer Risk in Southern Pakistani Patients
M. Iqbal (2015)
Are Hill's criteria for causality satisfied for vitamin D and periodontal disease?
W. Grant (2010)
Very low PSA concentrations and deletions of the KLK3 gene.
S. Rodriguez (2013)
Vitamin D and cancer: deciphering the truth.
S. Mocellin (2011)
Vitamin D and the social aspects of disease.
D. Grimes (2011)
Association between vitamin D receptor gene BsmI polymorphism and susceptibility to prostate cancer
Yuan-yuan Mi (2016)
Meta-analysis of the relation between vitamin D receptor gene BsmI polymorphism and susceptibility to ovarian cancer
Y. Zhang (2013)
Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the Prostate testing for cancer and Treatment study
R. Gilbert (2012)
Current progress in using vitamin D and its analogs for cancer prevention and treatment
F. S. Cheung (2012)
Genetic variations in VDR associated with prostate cancer risk and progression in a Korean population.
J. Oh (2014)
Common variation in the vitamin D receptor gene and risk of inflammatory bowel disease in an Irish case–control study
D. Hughes (2011)
Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and Progression
Scott M. Dehm (2019)
Determinants of vitamin D status: focus on genetic variations.
Diane Berry (2011)
Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose–response meta-analysis
R. Gilbert (2010)
Association between vitamin D receptor gene Cdx2 polymorphism and breast cancer susceptibility
Zhuchao Zhou (2013)
Prostate cancer in African-American men and polymorphism in the calcium-sensing receptor
G. Schwartz (2010)
Vitamin D and Cancer
L. Vuolo (2012)
Vitamin D: Genetics, Environment & Health
Charlotte Martin (2014)
Prostate cancer genomics, biology, and risk assessment through genome‐wide association studies
H. Nakagawa (2012)
Lack of association between the risk of prostate cancer and vitamin D receptor Bsm I polymorphism: a meta-analysis of 27 published studies
Shaosan Kang (2018)
Neurosteroid vitamin D system as a nontraditional drug target in neuropsychopharmacology
A. Stewart (2010)
Malignant Tumors of the Male Reproductive System
L. Richiardi (2014)
VitaminD , Sunlight and Prostate Cancer Risk
K. V. Donkena (2011)See more